Anesthetic

Meitheal Pharmaceuticals Announces Recent Business Progress Reinforcing Commitment to Sustainable Generics Development

Retrieved on: 
Tuesday, March 19, 2024
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, USP, Medication, NKF, ASHP, Fertility, Capital, Anesthetic, Society, Drug development, Nursing care plan, Bupivacaine, FDA, Food, Pharmaceutical industry

As we prepare to launch multiple new products in 2024, we are intently focused on expediting delivery of medicines in short supply,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals.

Key Points: 
  • As we prepare to launch multiple new products in 2024, we are intently focused on expediting delivery of medicines in short supply,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals.
  • As of March 1, 2024, both the U.S. Food and Drug Administration (FDA) and the American Society of Health-System Pharmacists (ASHP) websites list multiple presentations of Bupivacaine Hydrochloride Injection on drug shortage.
  • These approved lines add over 200 million units of capacity for vial and cartridge products that support current and future demand for generic injectables.
  • These lines are expected to produce commercial products that will have an impact on drug shortages beginning in the second half of 2024.

SKNV Gears Up to Increase Production Capacity Resulting from FDA's Recent Warnings

Retrieved on: 
Thursday, April 4, 2024
Physician, Freezing, Patient, FDA, Health care, Anesthetic, Agency, Sale, OTC, SKNV

POMPANO BEACH, Fla., April 4, 2024 /PRNewswire/ -- SKNV is increasing its manufacturing capacity to meet the growing demands of healthcare providers for topical numbing creams to support the FDA's recent efforts to combat unapproved and misbranded over-the-counter analgesic products. The Agency's warnings underscore the importance of prescribing Rx medications made from FDA-registered 503B outsourcing facilities, such as SKNV. SKNV's various prescription-based numbing formulations that offer different levels of potency are only made available to registered physicians at www.sknvnumbingcream.com.

Key Points: 
  • SKNV supports FDA's efforts to combat adverse effects associated with the use of OTC topical numbing creams for dermatologic procedures.
  • The Agency's warnings underscore the importance of prescribing Rx medications made from FDA-registered 503B outsourcing facilities, such as SKNV.
  • SKNV, an FDA-Registered 503B Outsourcing Facility, plays a critical role in ensuring that patients have access to quality topical numbing medications.
  • "SKNV manufactures a broad variety of topical numbing formulations providing prescribers a wide selection of solutions to choose from.

Ambulatory Management Solutions Rebrands to Ambulatory Anesthesia Care (AAC)

Retrieved on: 
Tuesday, March 26, 2024
Health, Anesthesia, EMR, Patient, Accreditation, Acquisition, Credentialing, MD, Quality of life, MBA, Anesthetic, MSO, AMS, Patient safety, CMO, Marketing, Pacific Northwest, AAC, Nursing

CHICAGO, March 26, 2024 /PRNewswire/ -- Ambulatory Anesthesia Care—formerly Ambulatory Management Solutions—began in 2007 when Chicago's Mobile Anesthesiologists, a pioneer of office-based anesthesia in operation since 1996, brought business services in-house.

Key Points: 
  • CHICAGO, March 26, 2024 /PRNewswire/ -- Ambulatory Anesthesia Care—formerly Ambulatory Management Solutions—began in 2007 when Chicago's Mobile Anesthesiologists , a pioneer of office-based anesthesia in operation since 1996, brought business services in-house.
  • AMS, now AAC, has continued to grow and help its practice partners set a new national standard in office-based anesthesia and perioperative services.
  • CEO Scott Mayer noted, "AAC has a unique approach to both ambulatory anesthesia, and healthcare.
  • Dr. Marlon Michel, MBA, founder, M2 Anesthesia , continued, "M2 Anesthesia has been delivering anesthetics to the Pacific Northwest's pediatric dental patients since 2009.

Enhancing Your Lips: Lip Flips vs. Lip Fillers

Retrieved on: 
Tuesday, February 27, 2024
Internet, Injection, Allergy, Bruise, Multimedia, Pain, Infection, Day, Injectable filler, Vascular occlusion, Swelling, Risk, Mouth, Safety, Hyaluronic acid, Lip, Tissue, Anesthetic, Cosmetics

When deciding between lip flips and lip filler, it's essential to consider your aesthetic goals, budget, and comfort level with each procedure.

Key Points: 
  • When deciding between lip flips and lip filler, it's essential to consider your aesthetic goals, budget, and comfort level with each procedure.
  • Let's dispel some of the most common misconceptions about lip flips and lip fillers.
  • Typically, the effects of lip fillers endure for around six months to one year, while lip flips generally last between 6 to 8 weeks.
  • Some people think that lip flips and lip fillers can cause long-term damage or change the structure of the lips.

ISMP Announces Three Additions to 2024-2025 Targeted Medication Safety Best Practices for Hospitals

Retrieved on: 
Thursday, February 22, 2024
Best practice, Member, Collection, Hospital, PSO, Tranexamic acid, Confusion, Vaccine, Risk, Internal bleeding, Safety, Health, Health care, Best, Reconciliation (United States Congress), Glass, Pharmacist, Organization, Patient, Patient safety organization, Sibling, Mortality, Anesthetic, Failure

PLYMOUTH MEETING, Pa., Feb. 22, 2024 /PRNewswire/ -- Healthcare organizations deciding on where to focus their medication safety efforts over the next two years now have updated recommendations from the Institute for Safe Medication Practices (ISMP). ISMP has released its 2024-2025 Targeted Medication Safety Best Practices for Hospitals to identify recurring problems that continue to cause fatal and harmful errors despite repeated warnings and mobilize widespread national action to prevent them.

Key Points: 
  • ISMP has released its 2024-2025 Targeted Medication Safety Best Practices for Hospitals to identify recurring problems that continue to cause fatal and harmful errors despite repeated warnings and mobilize widespread national action to prevent them.
  • ISMP's Best Practices help hospitals and health systems decide where to focus their medication safety efforts.
  • This year's list includes new Best Practices on preventing wrong-route errors with tranexamic acid, errors at transitions in care, and mistakes with vaccines in inpatient and outpatient settings.
  • "ISMP encourages hospitals and health systems to review this latest set of Best Practices and make implementation a priority," says Christina Michalek, BS, RPh, FASHP, Director of Membership and Patient Safety Organization (PSO).

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
Friday, January 26, 2024
Patient, Surgery, Infection, Research, Trauma, LAS, Analgesic, Injury, Diagnosis, Pain, Pain management, Rehabilitation, Ice, Nonsteroidal anti-inflammatory drug, Meditation, Anesthetic, USD, Physical examination, Burns, RICE, Lundbeck, QOL, Vertex Pharmaceuticals, Growth, Pharmaceutical industry

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
Friday, January 26, 2024
Patient, Surgery, Infection, Research, Trauma, LAS, Analgesic, Injury, Diagnosis, Pain, Pain management, Rehabilitation, Ice, Nonsteroidal anti-inflammatory drug, Meditation, Anesthetic, USD, Physical examination, Burns, RICE, Lundbeck, QOL, Vertex Pharmaceuticals, Growth, Pharmaceutical industry

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Retrieved on: 
Wednesday, January 24, 2024
System, Death, Allergy, Heron, Patient, Vitamin, Naproxen, Elective surgery, SAN, Health, Partnership, Foot, Gastrointestinal bleeding, Ibuprofen, Vomiting, Anemia, Ankle, Stroke, Heart failure, Medicine, Nonsteroidal anti-inflammatory drug, Patient satisfaction, Cartilage, Risk, Meloxicam, Pain, VAN, Cross-link, Food, Constipation, Pregnancy, NDA, Anesthetic, Aspirin, Tears, FDA, Ulcer, Liver, Boxed warning, New Drug Application, Headache, Bupivacaine, Human, Blood, Pharmaceutical industry

SAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.

Key Points: 
  • ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
  • This expanded indication for ZYNRELEF will now cover an estimated 13 million procedures annually, an estimated increase of 86% over prior indicated procedures.
  • To obtain this labeling expansion, Heron successfully conducted studies for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.
  • The most common side effects of ZYNRELEF are soft tissue procedures: vomiting and orthopedic procedures: constipation and headache.

Federal Court Enters Consent Decree Against Pharmasol for Distributing Adulterated Drugs

Retrieved on: 
Thursday, December 14, 2023
China Biologic Products, Safety, Heated tobacco product, Anesthetic, Justice, Complaint, Risk, Patient, Multimedia, Research, FDA, Animal, Vaccine, Health, Cosmetics, District court, Human services, Dietary supplement, Food, Failure, FD, Public, Pharmaceutical industry, Medical device, Badia

According to the complaint, which was filed along with the consent decree by the U.S. Department of Justice, Pharmasol and Badia unlawfully distributed adulterated drugs, meaning they do not comply with manufacturing quality requirements within the U.S. marketplace.

Key Points: 
  • According to the complaint, which was filed along with the consent decree by the U.S. Department of Justice, Pharmasol and Badia unlawfully distributed adulterated drugs, meaning they do not comply with manufacturing quality requirements within the U.S. marketplace.
  • In this case, the defendant's company distributed adulterated, poor-quality drugs without regard for patients and consumers," said Jill Furman, director of the Office of Compliance in the FDA's Center for Drug Evaluation and Research.
  • Pharmasol manufactures and distributes over-the-counter drugs, as well as human and animal prescription drugs such as topical corticosteroids and inhalant anesthetics.
  • According to the complaint, the defendants violated federal law under the FD&C Act by introducing drugs into interstate commerce that fail to comply with current good manufacturing practice requirements; therefore, these drugs are adulterated.

AANA Publishes Practice Considerations for Care of Transgender and Gender-Diverse Patients

Retrieved on: 
Thursday, November 16, 2023
Agent handling, Respiration, Policy, Anesthesia, DNP, Anesthetic, Pain management, Patient, Multimedia, Anesthesiology, Preoperative care, Certified Registered Nurse Anesthetist, Surgery, Trauma, CPPS, Nursing

ROSEMONT, Ill., Nov. 16, 2023 /PRNewswire/ -- To help ensure that all patients receive high-quality, safe pain management and anesthesia care, the American Association of Nurse Anesthesiology (AANA) has published its practice considerations for care of transgender and gender-diverse patients .

Key Points: 
  • ROSEMONT, Ill., Nov. 16, 2023 /PRNewswire/ -- To help ensure that all patients receive high-quality, safe pain management and anesthesia care, the American Association of Nurse Anesthesiology (AANA) has published its practice considerations for care of transgender and gender-diverse patients .
  • "The purpose of these practice and policy considerations is to highlight the impact of health inequities for transgender patients and how these may affect care outcomes.
  • The AANA recommends the personalized care during preoperative care also be applied to postoperative care for transgender patients.
  • AANA embraces members of the LGBTQIA+ community, including transgender and gender-diverse patients, and recognizes that nurse anesthesiologists play an integral role in promoting quality healthcare for these patients.